融合蛋白
细胞生物学
蛋白质结构域
囊泡相关膜蛋白8
体内
转基因
蛋白质工程
融合
功能(生物学)
FKBP公司
视网膜母细胞瘤样蛋白1
生物
小分子
蛋白质降解
化学
生物物理学
计算生物学
生物化学
重组DNA
遗传学
膜蛋白
基因
哲学
语言学
膜
酶
作者
Mark A. Sellmyer,Steve H. Thorne,Laura A. Banaszynski,Christopher H. Contag,Thomas J. Wandless
出处
期刊:CSH Protocols
[Cold Spring Harbor Laboratory]
日期:2009-03-01
卷期号:2009 (3): pdb.prot5173-pdb.prot5173
被引量:6
摘要
INTRODUCTION The ability to rapidly and reversibly perturb protein levels in living animals is a powerful tool for researchers to determine protein function in complex systems. We recently designed a small protein domain based on the 12-kDa FKBP (FK506 binding protein) that can be fused at either the carboxyl or amino terminus of a protein of interest. This destabilization domain (DD) confers instability to fusion protein partners, allowing targeted degradation of the protein of interest. A small molecule called Shield-1 binds to the DD and protects the fusion protein from degradation. Small-molecule-mediated post-translational regulation of protein stability affords this system rapid, reversible, and tunable control of protein levels and functions in a variety of model systems. Theoretically, a number of transgene delivery methods (e.g., viral, liposomal, or stem cell) can be used for the analysis of a DD fusion protein in an animal model. This protocol uses tumor xenografts in mice as one such mechanism for delivering the fusion protein and presents a method for delivering Shield-1 to regulate the fusion proteins in vivo.
科研通智能强力驱动
Strongly Powered by AbleSci AI